Table 1.

Summary of characteristics of the studies included in this review

Study ID	Setting	Participants	Samples	n	Comparator tests
Beckmann 2016	Switzerland	Children and adults Symptoms and fever not reported	NPS (199), BAL (76), others (7)	282	RespiFinder-221a
Brotons 2016	Spain	< 18 years with ALRI Fever not reported	NPA	320	Anyplex II RV16 assaya,b,c
Chan 2017	China	Children and adults with ARI Fever not reported	NPA	133	RT-PCR AND DFAa
Chen 2016	China	Patients with ARI Fever not reported	NPS	284	FilmArray RPa,d,e
Esposito 2016	Italy	Children with ARI in PICU and children with pneumonia by M. pneumoniae	NPS	185	xTAG RVP FAST v2a,c RT-PCR
Gonsalves 2019	USA, Canada	Children and adults with ARI Fever not reported	NPW	2132	xTAG RVPa,c OR bidirectional sequencing
Lee 2017	Singapore	Not reported	Respiratory samples	142	xTAG RVP FAST v2a,c
Locher 2019	Canada	Adults, mostly immunocompromised and with underlying chronic lung conditions, with ARI	Bronchoscopy collected samples	133	FilmArray RPa,d,e
Sails 2017	United Kingdom	“Symptomatic” Other characteristics not reported	NPS (122), throat swabs (53), endotracheal (47), BAL (17), others (122)	314	In-house multiplex RT-PCR panel
Tang 2016	USA	Patients with respiratory symptoms Fever not reported	NPS	404	FilmArray RPa,d,e

ALRI acute lower respiratory infection, ARI acute respiratory infection, BAL broncho-alveolar lavage, DFA direct immunofluorescence, n sample size, NPA nasopharyngeal aspirate, NPS nasopharyngeal swabs, RP respiratory panel; RVP respiratory virus panel

^aComplies with CE-IVD regulations

^bComplies with Canadian Department of Health regulations

^cComplies with Korea Food and Drug Administration regulations

^dComplies with the United States Food and Drug Administration regulations

^eComplies with Therapeutic Goods Administration regulations